Genmab A/S (NASDAQ:GMAB) Issues Earnings Results

Genmab A/S (NASDAQ:GMAB) announced its earnings results on Wednesday. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29, Zacks reports. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. Genmab A/S updated its FY 2025 guidance to EPS.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $19.69 on Thursday. The stock has a 50 day moving average of $20.68 and a 200 day moving average of $23.21. The firm has a market capitalization of $13.03 billion, a price-to-earnings ratio of 19.12, a PEG ratio of 0.54 and a beta of 0.96. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GMAB shares. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average target price of $42.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.